# Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/mdmb-4en-pinaca-schedule-i-placement/ > **Published:** 2026-04-25T23:32:54-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:57:26-04:00 > **Clinical Summary:** Learn about MDMB-4en-PINACA Schedule I placement by DEA, its risks, and regulatory updates under the Controlled Substances Act. --- ✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch  |  Federal Register PolicySafetyResearch Clinical Summary The U.S. Drug Enforcement Administration has placed MDMB-4en-PINACA, a synthetic cannabinoid, into Schedule I of the [Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/) Act, designating it as having high abuse potential and no accepted medical use. This synthetic compound, structurally similar to other illicit cannabinoids that have circulated in unregulated markets, poses significant [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) risks due to its potency and association with adverse effects including seizures, psychosis, and cardiovascular complications. The scheduling action reflects ongoing regulatory efforts to address the proliferation of novel synthetic cannabinoids that evade existing drug laws and appear in products marketed to consumers. For clinicians, this regulatory development underscores the importance of recognizing that patients presenting with severe cannabinoid toxicity or unexplained acute neuropsychiatric or cardiac symptoms may have consumed illicit synthetic cannabinoid products rather than regulated cannabis. Awareness of emerging synthetic cannabinoid threats complements counseling about the safety differences between regulated [medical cannabis products](https://cedclinic.com/cannabis-infused-products-skin-diy-topical-recipes/) and uncontrolled street drugs. Clinicians should remain informed about scheduling updates and educate patients that unregulated cannabinoid products carry unpredictable potency and contamination risks not present in tested [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/). Clinical Perspective ⚕️ The Drug Enforcement Administration’s scheduling of MDMB-4en-PINACA, a synthetic cannabinoid, reflects the ongoing regulatory challenge of keeping pace with novel psychoactive substances that continue to emerge faster than formal scheduling processes can address them. Synthetic cannabinoids carry distinct clinical risks—including severe psychiatric symptoms, acute kidney injury, and seizures—that differ meaningfully from plant-derived cannabis, yet patients may not recognize the distinction or may encounter these compounds marketed deceptively as legal alternatives. Clinicians should remain alert that scheduling alone does not eliminate availability or use; underground markets and evolving chemical analogs often circumvent regulatory action. When evaluating patients with unexplained acute psychiatric crises, cardiovascular events, or renal dysfunction, particularly in younger populations, synthetic cannabinoid use should be considered even if patients deny traditional [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/), and urine drug screening panels may not detect these compounds. A practical approach 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Schedules%20of%20Controlled%20Substances%3A%20Placement%20of%20MDMB-4en-PINACA%20in%20Schedule%20I%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2Fschedules-of-controlled-substances-placement-of-mdmb-4en-pinaca-in-schedule-i%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fschedules-of-controlled-substances-placement-of-mdmb-4en-pinaca-in-schedule-i%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Schedules%20of%20Controlled%20Substances%3A%20Placement%20of%20MDMB-4en-PINACA%20in%20Schedule%20I%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2Fschedules-of-controlled-substances-placement-of-mdmb-4en-pinaca-in-schedule-i%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I](https://cedclinic.com/synthetic-cannabinoids-schedule-i-designation/) Explore the DEA's scheduling of CUMYL-PEGACLONE, another synthetic cannabinoid, and its implications for [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) and regulation. [Read More](https://cedclinic.com/synthetic-cannabinoids-schedule-i-designation/) [DEA Places Synthetic Cannabinoid CUMYL-PEGACLONE in Schedule I](https://cedclinic.com/cumyl-pegaclone-schedule-i-placement-dea-synthetic-cannabinoid/) Detailed analysis of the DEA's decision to classify CUMYL-PEGACLONE as a Schedule I substance and its clinical relevance. [Learn More](https://cedclinic.com/cumyl-pegaclone-schedule-i-placement-dea-synthetic-cannabinoid/) [What are fentanyl, synthetic cannabinoids and why is Malaysia sounding the alarm?](https://cedclinic.com/what-are-fentanyl-synthetic-cannabinoids-and-why-is-malaysia-sounding-the-alarm/) An overview of synthetic cannabinoids and fentanyl, highlighting emerging global public health concerns including Malaysia's response. [Discover More](https://cedclinic.com/what-are-fentanyl-synthetic-cannabinoids-and-why-is-malaysia-sounding-the-alarm/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).